矛盾性、Lybalvi、Auvelity和Cobenfy：它们有什么共同之处？

IF 1.3 4区医学 Q3 PSYCHIATRY

Journal of Psychiatric Practice Pub Date : 2025-07-01 DOI:10.1097/PRA.0000000000000863

Sheldon H Preskorn

{"title":"矛盾性、Lybalvi、Auvelity和Cobenfy：它们有什么共同之处？","authors":"Sheldon H Preskorn","doi":"10.1097/PRA.0000000000000863","DOIUrl":null,"url":null,"abstract":"This column reviews 4 psychiatric combination products: Contrave (bupropion + naltrexone), Lybalvi (olanzapine + samidorphan), Auvelity (dextromethorphan + bupropion), and Cobenfy (xanomeline + trospium). All have been approved in the last 11 years. These medications are all based on planned and therapeutic drug interactions involving pharmacokinetics and/or pharmacodynamics. In each case, the second drug in the combination enhances the efficacy and/or reduces the adverse effects of the first drug. This review illustrates how basic science in pharmacokinetics and brain circuitry was fundamental to the development of these products, particularly in the case of Contrave and Cobenfy.","PeriodicalId":16909,"journal":{"name":"Journal of Psychiatric Practice","volume":"31 4","pages":"214-216"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Contrave, Lybalvi, Auvelity, and Cobenfy: What Do They Have in Common?\",\"authors\":\"Sheldon H Preskorn\",\"doi\":\"10.1097/PRA.0000000000000863\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This column reviews 4 psychiatric combination products: Contrave (bupropion + naltrexone), Lybalvi (olanzapine + samidorphan), Auvelity (dextromethorphan + bupropion), and Cobenfy (xanomeline + trospium). All have been approved in the last 11 years. These medications are all based on planned and therapeutic drug interactions involving pharmacokinetics and/or pharmacodynamics. In each case, the second drug in the combination enhances the efficacy and/or reduces the adverse effects of the first drug. This review illustrates how basic science in pharmacokinetics and brain circuitry was fundamental to the development of these products, particularly in the case of Contrave and Cobenfy.\",\"PeriodicalId\":16909,\"journal\":{\"name\":\"Journal of Psychiatric Practice\",\"volume\":\"31 4\",\"pages\":\"214-216\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Psychiatric Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/PRA.0000000000000863\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychiatric Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/PRA.0000000000000863","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

摘要

本专栏回顾了4种精神科联合用药：Contrave（安非他酮+纳曲酮）、Lybalvi（奥氮平+ samidorphan）、Auvelity（右美沙芬+安非他酮）和Cobenfy （xanomeline + trospium）。所有这些都是在过去11年里获得批准的。这些药物都是基于计划和治疗药物相互作用，包括药代动力学和/或药效学。在每种情况下，组合中的第二种药物增强第一种药物的功效和/或减少第一种药物的不良反应。这篇综述说明了药物动力学和脑回路的基础科学如何对这些产品的开发至关重要，特别是在contrve和Cobenfy的情况下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Contrave, Lybalvi, Auvelity, and Cobenfy: What Do They Have in Common?

This column reviews 4 psychiatric combination products: Contrave (bupropion + naltrexone), Lybalvi (olanzapine + samidorphan), Auvelity (dextromethorphan + bupropion), and Cobenfy (xanomeline + trospium). All have been approved in the last 11 years. These medications are all based on planned and therapeutic drug interactions involving pharmacokinetics and/or pharmacodynamics. In each case, the second drug in the combination enhances the efficacy and/or reduces the adverse effects of the first drug. This review illustrates how basic science in pharmacokinetics and brain circuitry was fundamental to the development of these products, particularly in the case of Contrave and Cobenfy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Psychiatric Practice PSYCHIATRY-

CiteScore

2.30

自引率

10.50%

发文量

159

审稿时长

>12 weeks

期刊介绍： Journal of Psychiatric Practice® seizes the day with its emphasis on the three Rs — readability, reliability, and relevance. Featuring an eye-catching style, the journal combines clinically applicable reviews, case studies, and articles on treatment advances with practical and informative tips for treating patients. Mental health professionals will want access to this review journal — for sharpening their clinical skills, discovering the best in treatment, and navigating this rapidly changing field. Journal of Psychiatric Practice combines clinically applicable reviews, case studies, and articles on treatment advances with informative "how to" tips for surviving in a managed care environment.